NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

The Nordic biotech and healthcare stocks created opportunities for investors with a risk appetite for yet another week. In the past week, Curasight presented an accelerated strategy with an additional clinical study as well as an MDKK 51.2 rights issue, Biosergen received regulatory approval to test BSG005 in patients with invasive fungal infection, and Genmab announced its annual results for 2023 with many new price targets following.

8 of the 20 companies had a positive share price development the past week and 7 companies have had a positive share price performance year-to-date. Y-mAbs Therapeutics is still the best-performing Danish stock year-to-date with a 139% return and Xbrane Biopharma AB was the best Nordic investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Ascendis Pharma

No news the past week

Biosergen

Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection (Link)

Cessatech

No news the past week

CS Medica

CS Medica presented its annual report for 2022/2023 (Link) and will host a conference call on February 21. You can live-stream the earnings call via this link at 10 AM CET.

Notice of Shareholders’ Annual General Meeting (Link)

Evaxion Biotech

No news the past week

Curasight

Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy (Link)

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company (Link)

You can read our comments on the rights issue and accelerated strategy here (in Danish)

ExpreS2ion

No news the past week

Fluoguide

No news the past week

Genmab

Genmab published its annual report for 2023 (Link)

Genmab got new price targets following their annual report. DKK 2720 (Carnegie), DKK 2630 (DNB), DKK 2150 (Jeffries), and DKK 2284 (Goldman Sachs), The stock currently trades at 1989 DKK.

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona resolves on a directed issue of units to guarantors in connection with the completed rights issue and a directed issue of convertibles of SEK 10 million (Link)

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 (Links)

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of -0,4%. The most notable news was Curasight which presented an accelerated therapeutic strategy with an additional clinical study and a capital raise of above MDKK 51. Biosergen also received regulatory approval to start testing its lead candidate BSG005 in patients with invasive fungal infection. Genmab presented its annual report which attracted significant interest and updated price targets. Finally, more financial results are to come with CS Medica and Y-mAbs Therapeutics reporting in the coming weeks. The best stocks year-to-date are Y-mAbs Therapeutics, CS Medica, and Expres2ion Biotech Holding with 36-139% increases already after seven weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 6%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 1.4% to 62.20. The index was previously recovering from the all-time low in October of 57.12 but is now on a downward trajectory again. In the past 12 months, it has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down approx. 23.5%.

The index development for Kapital Partner Healthcare Index the past 12 months

36-83% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

Xbrane Biopharma AB (83%) (Nordnet) specializes in biosimilars where they try to replicate existing biologics on the market. They do not improve the existing drugs but try to make them available at a lower cost using a patented platform technology that provides significantly lower production costs compared to competing systems. The company has one product on the market in the EU together with Stada.

Diagonal Bio AB (79%) (Nordnet) is developing a platform called Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service, and associated ancillary services are also offered. Last week the company signed a distribution agreement with Techtum Lab AB regarding the rights to distribute Diagonal Bio’s analytical instrument, LAMPlify®, in Sweden until May 30, 2025, with an option for a 12-month renewal. 

Xspray Pharma AB (36%) (Nordnet) has several product candidates in the clinical development phase and plans to launch its first product on the US market during September 2024. Based on a patented technology for the amorphous formulation of drugs, the company develops product candidates with relevant medical benefits that should be able to be marketed as improved versions of established drugs for the treatment of cancer 

Sources: Refinitiv & Nordnet